Should we ban B6 supplementation of INH therapy in childhood tuberculosis?
Mathur
G P
GP
Department of Pediatrics, G.S.V.M. Medical College, Kanpur.
Mathur
S
S
Rastogi
S
S
D002648:Child; D003906:Developing Countries; D004359:Drug Therapy, Combination; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage* / Q000009:adverse effects; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced / Q000517:prevention & control; D011502:Protein-Energy Malnutrition / Q000188:drug therapy; D011736:Pyridoxine / Q000008:administration & dosage* / Q000009:adverse effects; D012293:Rifampin / Q000008:administration & dosage / Q000009:adverse effects; D012307:Risk Factors; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*; D026681:Vitamin B 6 Deficiency / Q000139:chemically induced / Q000517:prevention & control
D011736:Pyridoxine; D007538:Isoniazid; D012293:Rifampin